Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century
Last to the game in the current generation of CAR-T cell therapies, Bristol Myers Squibb has wasted no time trying to challenge its closest rivals’ head start while keeping an eye to the future. On the latter front, the drug giant has now signed a deal with a small next-gen cell therapy player to get a leg up.
Bristol Myers will pay $100 million in upfront cash and make an additional $50 million equity investment in Century Therapeutics for access to up to four off-the-shelf engineered cell therapies derived from donor stem cells, the partners said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.